Compare Main Street Capital Corporation (MAIN) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Main Street Capital Corporation vs Viatris Inc — how do they compare? Main Street Capital Corporation trades at $59 (market cap $5.52B), while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: Viatris Inc is far larger — about 3.4× Main Street Capital Corporation's market cap, and Main Street Capital Corporation pays the higher dividend (5.39%). Which is the better fit depends on your goals.
| MAIN | VTRS | |
|---|---|---|
Market Cap | $5.52B | $18.69B |
Sector | Financials | Health |
52-Week High | $67.54 | $17.86 |
52-Week Low | $49.63 | $9.49 |
Dividend Yield | 5.39% | 2.95% |
Enterprise Value | — | $30.80B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
